EP3160451B1 - Formulations de cannabinoïde buccale et sublinguale, et leur procédé de fabrication - Google Patents

Formulations de cannabinoïde buccale et sublinguale, et leur procédé de fabrication Download PDF

Info

Publication number
EP3160451B1
EP3160451B1 EP15812123.6A EP15812123A EP3160451B1 EP 3160451 B1 EP3160451 B1 EP 3160451B1 EP 15812123 A EP15812123 A EP 15812123A EP 3160451 B1 EP3160451 B1 EP 3160451B1
Authority
EP
European Patent Office
Prior art keywords
troche
cbd
peg
thc
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15812123.6A
Other languages
German (de)
English (en)
Other versions
EP3160451A4 (fr
EP3160451A1 (fr
Inventor
Kenton L. Crowley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farm To Farma Inc
Original Assignee
Farm To Farma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farm To Farma Inc filed Critical Farm To Farma Inc
Publication of EP3160451A1 publication Critical patent/EP3160451A1/fr
Publication of EP3160451A4 publication Critical patent/EP3160451A4/fr
Application granted granted Critical
Publication of EP3160451B1 publication Critical patent/EP3160451B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • the embodiments of the present invention relate to the delivery of cannabinoids via lozenge or troche.
  • Cannabis commonly known as marijuana and by numerous other names, is a preparation of the cannabis plant intended for use as a psychoactive drug and as medicine.
  • the principal psychoactive constituent of cannabis is tetrahydrocannabinol (THC) representing one of hundreds of known compounds in the plant, including many other cannabinoids, such as cannabidiol (CBD), cannabinol (CBN), tetrahydrocannabivarin (THCV) and cannabigerol (CBG).
  • CBD cannabidiol
  • CBD cannabinol
  • THCV tetrahydrocannabivarin
  • CBG cannabigerol
  • Cannabis-based products contain harmful preservatives (e.g., BHT, BHA) and stabilizers, artificial flavorings, colors, as well as toxic byproducts (e.g., Benzene, Hexane, heavy metals, etc.) from extraction methods, and/or trigger side effects and fail to provide effective relief for the subject medical condition.
  • harmful preservatives e.g., BHT, BHA
  • stabilizers e.g., artificial flavorings, colors
  • toxic byproducts e.g., Benzene, Hexane, heavy metals, etc.
  • the present invention provides a troche according to claims 1 to 10.
  • a cannabinoid lozenge or troche comprising polyethylene glycol (or other bases such as gelatin, pectin, fatty acids (e.g., MBK), waxes, etc.) and oils of peppermint (or other oils and extracts) which is administered buccally and/or sublingually.
  • These dosage forms demonstrate an improved efficacy with reduced side effects when compared to formulations of cannabinoids in capsules, oral solutions, tinctures, sprays and edibles.
  • the embodiments of the present invention avoid harmful preservatives (e.g., BHT, BHA) and stabilizers, avoiding artificial sweeteners and colors, while addressing sub- therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids, terpenes and flavonoids. Moreover, embodiments of the present invention allow for accurate and reproducible therapeutic effects with ease of dosage adjustments. It is important to recognize that the troche is able to be accurately cut into as small as 1/16th of a dose, allowing broad dosage range adjustment from a single troche. The present invention also provides a method of making a troche according to claim 11.
  • the embodiments of the present invention are useful for the treatment and prevention of a wide range of disorders, including, for example, inflammatory bowel disease (IBS), Crohn's disease (CD), irritable bowel syndrome (IBS), ulcerative colitis (UC), nausea, vomiting, anorexia, cachexia, all forms of pain (i.e. acute, chronic, neuropathic, etc.), gastrointestinal tract distress (i.e.
  • the actives used in the embodiments of the present invention affect the human physiology in positive ways including the improvement of the immune system, prevention or treatment of certain cancers, and reduction of inflammation. Those skilled in the art will recognize that the embodiments of the present invention may be used to treat any and all medical conditions that respond favorably thereto.
  • CBD cannabinoids
  • CBDA CBDA
  • CBG CBGA
  • CBC CBCA
  • Delta-9 THCA Delta-9 THC
  • Delta-8 THC Delta-8 THC
  • the embodiments of the present invention also recognize the importance of the ratios of each of the aforementioned actives.
  • cannabinoids are also temperature sensitive and the embodiments of the present invention recognize the significance of temperature during each relevant step of making the product. For instance, keeping the temperature controlled along with the amount of the acid form of THC and/or CBD may have a profound effect on certain conditions mentioned earlier.
  • the embodiments of the present invention are directed to a dosage form that is solid at room temperature.
  • the dosage form is a lozenge or troche.
  • the product may be refrigerated or frozen without harm.
  • the lozenge or troche dissolves at body temperature within the mouth of a user where the majority of absorption takes place resulting in optimizing the dose absorbed and avoiding the variables of oral absorption and first pass metabolizm.
  • Formulation begins by combining polyethylene glycol with approximate molecular weights of 1300 to 1650 g/mol with specific forms of gum acacia, citric acid, stevia extract powder, oils of peppermint, menthol and cream de mint at specific temperatures with a range of cannabis extracts providing specific doses that include the following compositions singularly or in combination: (i) Delta-9 Tetrahydrocannabinol in the decarboxylated form in doses ranging from 5 mg to 240 mg (0.5% to 25.26% by weight); (ii) Tetrahydrocannabinolic acid (THC-A in the natural, non-decarboxylated form) in doses of 5 mg to 240 mg (0.5% to 25.26% by weight); (iii) Cannabidiol (CBD) in doses of 5 mg to 240 mg with a Delta-9 THC content less than or equal to 0.3 mg (making this dosage form legal in all states of the United States); and Cannabidiol (CBD) in doses
  • Another possible active includes Delta-8 Tetrahydrocannabinol.
  • Other oils such as sweet orange oil, ginger oil, mango, tangerine, etc., may be substituted or used in combination with oils of peppermint, menthol and cream de mint.
  • the dosage range may increase to 500 mg with the use of pure Cannabidiol or Tetrahydrocannabinol (i.e., crystals).
  • Temperature control is necessary in the processing of cannabis extracts.
  • the embodiments of the present invention recognize and use temperatures necessary to optimize cannabinoid, terpene and flavonoid content and ratios. Temperatures in the range of approximately -78°C to 100°C (-109°F to 212°F) (at normal atmospheric pressure; temperatures change with negative pressures which allow for extraction and processing using different methods), maintain certain percentages of all cannabinoids and retain natural terpene and flavonoid content in the extracts thereby resulting in more medicinal value being retained instead of isolating one active. Notwithstanding the importance of the natural mixture of actives, it has been recognized in the instant embodiments of the present invention that one active can be used in the troche providing its own unique physiologic and clinical value.
  • Cannabis, C. sativa, C. indica, C. ruderalis and hybrids in the raw material are used to create specific ratios of CBD to THC.
  • Percentages range from 24000:1 CBD:THC (i.e., 240 mg CBD to 0.01 mg THC) to 1:24000 CBD:THC (i.e., 0.01 mg CBD to 240 mg THC).
  • percentages range 200,000:1 CBD:THC and 1:200,000 CBD:THC.
  • the embodiments of the present invention contemplate dosage forms with a total weight of between approximately 0.5 grams and 2.01 grams, depending on the formulation of the actives, size of the lozenge or troche.
  • This dosage form can be used for all natural, semi-synthetic and synthetic derivatives of all cannabinoids. Handling and processing of the extract is significant in the proper delivery of the actives with the associated terpenes and flavonoids, all which synergistically work to improve the medicinal value of the cannabinoids chosen for the particular ailment under treatment.
  • Assembly of the lozenge or troche may comprise: (i) preparing a proprietary base of polyethylene glycol with molecular weights of 1300 to 1650 g/mol, gum acacia, stevia extract, citric acid and Magnasweet® (formed of base products comprising Monoammonium Glycyrrhizinate and Ammonium Glycyrrhizinate) by melting the same at a temperature of approximately 58°C to 64°C at normal atmospheric pressure; (ii) adding the desired cannabis extract in amount based on the goals of the dosage per troche, symptom treatment or disease state treatment (e.g., 20 mg CBD dose with 1-2 mg of THC is effective for treating patients with autism, arthritis, and seizures); (iii) adding desired essential oils based on the treatment goals, flavoring and/or allergy avoidance; and (iv) adding solution to a lozenge or troche mold device to deliver accuracy of dosage desired. Range of standard deviation is ⁇ 5% in weight and less than 10% stated active goals.
  • An exemplary method of producing 900 troches comprises: (i) measuring 670 grams of PEG 1450 (or PEG 1500 +/- PEG 300) (the 670 grams of PEG makes up approximately 75% to 90% total weight); (ii) melting the 670 grams of PEG to a maximum temperature of approximately 60°C- 70°C (many devices work; stir/hot plate, heated mix/pump/delivery automation - if used under vacuum, temperatures will be lower under automation assembly lines); (iii) once the PEG is melted, adding powders (citric acid - 0.17% to 1.2% by weight, Luo Han Gou - 0.46% to 3.1% by weight, acacia gum - 0.08% to 2.0%, and Magnasweet® - 0.02% to 0.06% by weight) and mixing until suspended uniformly; (iv) adding 1 mg to 500 mg of active CBD and THC to each troche in ratios of 24000:1 to 1:1500 (e.g., for a 5mg troche add 2.5 mg of CBD and
  • Another exemplary method, according to the claims, of producing 900 troches each including 60mg of THC with approximately 4mg of CBD comprises: (i) measuring 772gm of PEG 1450 (or PEG 1500 +/- PEG 300) (the PEG makes up approximately 87% of total weight, based on a 62.5% THC oil containing 5.1% CBD); (ii) melting the 772gm of PEG to a maximum temperature of approximately 60°C-70°C (many devices work; stir/hot plate, heated mix/pump/delivery automation - if used under vacuum, temperatures will be lower under automation assembly lines); (iii) once the PEG is melted, adding 86.4gm stated concentration cannabis extract oil; (iv) adding a mixed set of powders (citric acid - 0.17% to 1.2% by weight, Luo Han Gou - 0.46% to 3.1% by weight, acacia gum - 0.08% to 2.0% by weight, and Magnasweet® - 0.02% to 0.06% by weight)
  • An exemplary method of producing 120 gelatin-based troches that are 40mg total (24mg CBD and 16mg CBD) using a 500mg THC/CBD per gram concentration cannabis extract oil comprises: (i) measuring 122.5gm gelatin (special gelatin base making up approximately 91% of total weight, again depending on extract concentration) and melting (many different methods to melt) to a temp of approximately 34°C-40°C; (ii) once melted, adding 7.2 grams of active (based on stated concentration) using a sir/hot plate or other mixing device including a closed automated injection system, (iii) adding a mixed set of powders (in approximate amounts of the following: Luo Han Gou - 0.25% to .45% by weight, acacia gum - 0.6% to 1.1% by weight, citric acid - 0.5% to 0.8% by weight, Magnasweet® 0.04% to 0.06% by weight and silica - 0.32% to 0.81% by weight) and mixing until suspended uniformly; (iv) adding organic essential oils (
  • Pectin may also be used to produce the troches. Polysaccharides formed of pectin or gelling agents can modify the density of the gelatin troche are in the range of 20,000 to 400,000 g/mol molecular weight. As set forth above, the gelatin-based troche may also include Silica Gel or Silicon Dioxide for purposes of dispersing ingredients.
  • the formulations set forth above are exemplary such that variations fall within the scope of the present invention.
  • the amount of oil used may vary based on concentration. More specifically, when using 560mg THC/1gm oil versus 764mg THC/1gm oil, the PEG base volume changes appropriately to maintain volume and correct dose, but density and weight changes.
  • different oils may be used in different amounts. For example, ginger is a potent oil such that a few drops may suffice whereas other oils may be used in units of milliliters.
  • the combinations of oils may also differ.
  • a formulation may include peppermint oil but no extra menthol or cream de mint while another formulation may use ginger, orange and mint oil.
  • the oils provide a desired level of flavoring in addition to the therapeutic value of oils (e.g., peppermint oil).
  • the troche can be made using the PEG, , cannabis extract, Luo Han Gou and optionally one or more of the following: gum acacia, citric acid, stevia extract powder, or, Monoammonium Glycyrrhizinate and Ammonium Glycyrrhizinate.
  • the embodiments of the present invention demonstrate an improved efficacy that is unexpected compared to utilizing the same dose of the same active source of cannabis oil.
  • the formulation comprising PEG and high dose mint oil formula provides unexpected results as described herein.
  • a high concentration (99%-99.9%) CBD derived from hemp is used to achieve the desired ratio.
  • the ratios are determined by the strain of cannabis that includes different amounts of CBD and THC.
  • the embodiments of the present invention avoid the traditional pitfalls of medicating with other orally ingested cannabinoids such as capsules, elixirs, infused food products, sprays, etc., and topically applied agents.
  • the lozenge or troche provides clear separation from the confusion associated with traditional preparations of natural cannabinoid infused products, including candy bars, chocolate, butter, baked goods, etc., that produce unreliable and varied clinical responses that are not always the same or reproducible.
  • the use of the lozenge or troche offers a method of reduced variability in the pharmacokinetics of the cannabinoids resulting in clinical outcomes that are consistent from dose to dose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Claims (15)

  1. Tablette comprenant :
    un polyéthylène glycol ; des extraits de cannabis comprenant un rapport souhaité de cannabidiol (CBD) sur tétrahydrocannabinol (THC), et du Luo Han Gou.
  2. Tablette selon la revendication 1 comprenant :
    PEG 1450 ou PEG 1500 ± PEG 300 ; et des extraits de cannabis comprenant un rapport de 24 000:1 à 1:24 000 de CBD sur THC, ledit extrait de cannabis comportant l'un ou plusieurs parmi les suivants : des cannabinoides, des terpènes et des flavonoïdes.
  3. Tablette selon la revendication 1 ou la revendication 2 comprenant en outre l'un ou plusieurs parmi les suivants : gomme arabique, acide citrique, poudre d'extrait de stevia, Glycyrrhizinate de Monoammonium et Glycyrrhizinate d'Ammonium.
  4. Tablette selon la revendication 1 comprenant en outre une ou plusieurs huiles organiques ou tablette selon la revendication 2 comprenant en outre une ou plusieurs huiles.
  5. Tablette selon la revendication 1, ledit polyéthylène glycol étant choisi parmi PEG 1450 et PEG 1500 ± PEG 300.
  6. Tablette selon la revendication 4, ladite ou lesdites huiles étant choisies parmi la menthe poivrée, l'orange douce, le gingembre, la mandarine et la mangue.
  7. Tablette selon la revendication 1 ou la revendication 2 comprenant en outre du menthol et/ou de la crème de menthe.
  8. Tablette selon la revendication 1, ledit rapport de CBD sur THC étant dans une plage de 24 000:1 à 1:24 000.
  9. Tablette selon la revendication 1 ou la revendication 2, lesdits extraits de cannabis comprenant l'un ou plusieurs parmi les suivants :
    (i) Delta-9 tétrahydrocannabinol sous la forme décarboxylée ;
    (ii) Acide tétrahydrocannabinolique sous la forme naturelle, non décarboxylée ;
    (iii) Cannabidiol doté d'une teneur en Delta-9 THC inférieure ou égale à 0,3 mg/g ; et Cannabidiol (CBD) en combinaison avec Delta-9 tétrahydrocannabinol en un rapport de 2 % à 6 % de formes décarboxylées et non décarboxylées ; et
    (iv) Delta-8 tétrahydrocannabinol.
  10. Tablette selon la revendication 1 ou la revendication 2, une concentration dudit CBD étant de 99 % à 99,9 %.
  11. Procédé de préparation d'une tablette comprenant :
    (i) la préparation d'une base de polyéthylène glycol ;
    (ii) l'ajout de l'extrait de cannabis souhaité en une quantité basée sur les objectifs de traitement de symptômes ou de traitement d'état maladif ; et
    (iii)l'ajout de Luo Han Gou.
  12. Procédé selon la revendication 11 comprenant en outre l'ajout d'un ou plusieurs parmi les suivants : gomme arabique, acide citrique, poudre d'extrait de stevia, Glycyrrhizinate de Monoammonium et Glycyrrhizinate d'Ammonium ; ou
    comprenant en outre l'ajout de menthol et/ou de crème de menthe.
  13. Procédé selon la revendication 12 comprenant en outre
    l'ajout d'une ou plusieurs huiles organiques souhaitées sur la base des objectifs de traitement, de l'arôme et/ou de l'évitement d'une allergie ;
    par exemple l'ajout d'une ou plusieurs huiles choisies parmi la menthe poivrée, l'orange douce, le gingembre, la mandarine et la mangue.
  14. Produit pharmaceutique sous la forme de la tablette selon l'une quelconque des revendications 1 à 10.
  15. Tablette selon l'une quelconque des revendications 1 à 10 ou produit pharmaceutique selon la revendication 14 pour une utilisation dans le traitement d'une maladie intestinale inflammatoire (IBS), de la maladie de Crohn (CD), du syndrome de l'intestin irritable (IBS), d'une colite ulcéreuse (UC), de la nausée, des vomissements, de l'anorexie, de la cachexie, de toutes les formes de douleur (c'est-à-dire aiguë, chronique, neuropathique, etc.), d'une détresse du tractus gastro-intestinal (c'est-à-dire des brûlures d'estomac, une indigestion, des maux d'estomac, etc.), de maux de tête dus à une migraine, d'un syndrome post-menstruel (PMS), d'un cancer, de maladies neurodégénératives comme la maladie de Lou Gehrig, la maladie de Huntington, la démence d'Alzheimer, la maladie de Parkinson et les symptômes de type parkinsonien, de lésions de la moelle épinière ; du VIH/SIDA, de l'agitation, de l'insomnie, de la dépression, de spasmes musculaires, d'une spasticité provenant d'une sclérose en plaques, d'un glaucome, d'un trouble du spectre autistique (ASD), d'un trouble d'hyperactivité avec déficit de l'attention (ADHD), d'un trouble de stress post-traumatique (PTSD), et de troubles de l'anxiété.
EP15812123.6A 2014-06-27 2015-06-26 Formulations de cannabinoïde buccale et sublinguale, et leur procédé de fabrication Active EP3160451B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462018484P 2014-06-27 2014-06-27
PCT/US2015/038132 WO2015200864A1 (fr) 2014-06-27 2015-06-26 Formulations de cannabinoïde buccale et sublinguale, et leur procédé de fabrication

Publications (3)

Publication Number Publication Date
EP3160451A1 EP3160451A1 (fr) 2017-05-03
EP3160451A4 EP3160451A4 (fr) 2018-07-04
EP3160451B1 true EP3160451B1 (fr) 2021-04-07

Family

ID=54929361

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15812123.6A Active EP3160451B1 (fr) 2014-06-27 2015-06-26 Formulations de cannabinoïde buccale et sublinguale, et leur procédé de fabrication

Country Status (6)

Country Link
US (2) US9675656B2 (fr)
EP (1) EP3160451B1 (fr)
AU (2) AU2015279612A1 (fr)
CA (1) CA2953684C (fr)
ES (1) ES2877361T3 (fr)
WO (1) WO2015200864A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015279612A1 (en) 2014-06-27 2017-02-02 Kenton L. Crowley Buccal and sublingual cannabinoid formulations and method of making the same
WO2016181394A1 (fr) * 2015-05-13 2016-11-17 One World Cannabis Ltd Utilisation du cannabis pour traiter la fibromyalgie, méthodes et compositions associées
CA2981772C (fr) * 2016-02-11 2018-12-18 Gelpell Ag Formulations orales solides de cannabinoides, leurs procedes de production et d'utilisation
EP3413903A4 (fr) * 2016-02-12 2019-09-18 Synergistic Therapeutics, LLC Tablette sublinguale d'antidépresseur
MX2018012685A (es) * 2016-04-18 2019-06-06 Michael Morrow Kenneth Aislamiento de extractos de plantas.
KR20210013645A (ko) 2016-08-03 2021-02-04 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
WO2018089863A1 (fr) * 2016-11-11 2018-05-17 Bennes, Inc. Formulations pour administration efficace de cannabinoïdes
US11007170B2 (en) 2017-02-02 2021-05-18 Panaxia Pharmaceutical Industries Ltd. Composition for buccal or sublingual administration of cannabis extract and methods for making same
EP3576731B1 (fr) * 2017-02-02 2022-03-23 Panaxia Pharmaceutical Industries Ltd. Composition pour l'administration buccale ou sublinguale d'extrait de cannabis et ses procédés de production
CN108853079A (zh) * 2017-05-15 2018-11-23 汉义生物科技（北京）有限公司 大麻素类化合物在治疗肠易激综合征中的应用
US20200281890A1 (en) * 2017-09-25 2020-09-10 Canopy Health Innovations Compositions comprising cannabidiol, tetrahydrocannabinol, terpenes, and flavonoids and use thereof in the treatment of insomnia
ES2907325T3 (es) 2017-09-28 2022-04-22 Zynerba Pharmaceuticals Inc Tratamiento de síndrome del cromosoma X frágil y autismo con cannabidiol
WO2019104291A1 (fr) * 2017-11-27 2019-05-31 La'au Pono Combinaison de poudre d'extrait botanique séché granulé pour soulager des symptômes
US20190321330A1 (en) * 2018-04-18 2019-10-24 Canopy Growth Corporation Cannabis placebo compositions, delivery vehicles and a method for colour matching/neutralization of cannabis products
US11376227B2 (en) 2018-09-04 2022-07-05 Babak Ghalili Cannabinoid and menthol gum and lozenge compositions and methods
US20210290562A1 (en) 2018-12-11 2021-09-23 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
KR20210104084A (ko) 2018-12-14 2021-08-24 지네르바 파마슈티컬스, 인코포레이티드 칸나비디올을 사용하는 22q11.2 결실 증후군의 치료
WO2020220092A1 (fr) * 2019-05-01 2020-11-05 Cannadol Pharmaceuticals Compositions et procédés pour le soulagement de la douleur et de l'anxiété
EP4009800A4 (fr) * 2019-08-06 2023-08-16 Nuka Enterprises Compositions consommables et leurs procédés de production
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
AU2020366147B2 (en) 2019-10-14 2024-09-05 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US11596618B2 (en) * 2020-01-15 2023-03-07 Resurgent Biosciences, Inc. Oral cannabinoid delivery formulations with mouthfeel experience enhancers
WO2021177942A1 (fr) * 2020-03-03 2021-09-10 Babak Ghalili Compositions de pastilles de cannabinoïdes et de gomme de menthol et procédés associés
IT202000012463A1 (it) * 2020-05-26 2021-11-26 Sofar Spa Composizioni comprendenti un derivato della cannabis sativa e ceppi di batteri e loro uso terapeutico
IT202000012448A1 (it) * 2020-05-26 2021-11-26 Sofar Spa Composizioni comprendenti un derivato della cannabis sativa e ceppi di batteri e loro uso terapeutico
US20210369802A1 (en) * 2020-06-01 2021-12-02 James Chuang Cannabis plant formulations and methods of delivery
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CA3217137A1 (fr) 2021-04-29 2022-11-03 Christopher Adair Formulations dans lesquelles le cannabidiol est le constituant dominant, leurs procedes de fabrication et leurs utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
FI113340B (fi) * 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
US20040241223A1 (en) 2003-05-27 2004-12-02 David Wong Oral dosage forms for macromolecular drugs
EP2063861B1 (fr) * 2006-09-15 2015-02-25 Echo Pharmaceuticals B.V. Unité posologique pour administration sublinguale, buccale ou orale de substances actives pharmaceutiques insolubles dans l'eau
US20080181942A1 (en) * 2006-11-30 2008-07-31 University Of Plymouth Delta-9-THC compositions and methods for treating symptoms associated with multiple sclerosis
US20100285098A1 (en) 2007-09-11 2010-11-11 Haley Jeffrey T Adhering troches with santacid for treatment of throat esophagus and stomach
US20120043242A1 (en) * 2010-08-19 2012-02-23 Andrew David Hospodor Medicinal cannabis fatty foodstuff
US20140166027A1 (en) * 2012-12-14 2014-06-19 Richard C. Fuisz Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor Producing Device Through Use of an Absorption Conditioning Unit
EP2934512B1 (fr) * 2012-12-18 2021-11-24 Kotzker Consulting LLC Utilisation de cannabinoïdes et de terpènes pour le traitement d'une toxicité d'organophosphate et de carbamate
AU2015279612A1 (en) 2014-06-27 2017-02-02 Kenton L. Crowley Buccal and sublingual cannabinoid formulations and method of making the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
AU2020210223A1 (en) 2020-08-20
US9675656B2 (en) 2017-06-13
CA2953684C (fr) 2023-01-03
US10420809B2 (en) 2019-09-24
WO2015200864A1 (fr) 2015-12-30
US20170274030A1 (en) 2017-09-28
EP3160451A4 (fr) 2018-07-04
EP3160451A1 (fr) 2017-05-03
CA2953684A1 (fr) 2015-12-30
US20150374770A1 (en) 2015-12-31
ES2877361T3 (es) 2021-11-16
AU2015279612A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
EP3160451B1 (fr) Formulations de cannabinoïde buccale et sublinguale, et leur procédé de fabrication
US10525093B2 (en) Cannabinoid formulations and method of making the same
US11426434B2 (en) Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
CA3046638A1 (fr) Formulations pour administration efficace de cannabinoides
US20210236575A1 (en) Therapeutic combinations of cannabinoids with curcumin
CA2568997A1 (fr) Compositions pharmaceutiques destinees au traitement de l'arthrite et/ou de ses symptomes
US20210205236A1 (en) Therapeutic combinations of boswellia extract and cannabinoids
US20210401766A1 (en) Method of Using Cannabinoids Encapsulated in Phospholipid Carriers for Transmucosal and Transdermal Administration
EP3789012A1 (fr) Cannabinoïdes encapsulés dans des supports de phospholipides pour administration transmucosale et transdermique
US20220062360A1 (en) Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
WO2020072499A1 (fr) Compositions de phénol ultra pur
US11285184B2 (en) Cannabidiol alkaline composition
WO2020073032A1 (fr) Systèmes et procédés permettant de combiner des cannabinoïdes et une solution à base de sucre, et de créer des comprimés à dissolution buccale
CA3060909A1 (fr) Procede d'encapsulation de cannabinoides dans des supports de phospholipides

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FARM TO FARMA, INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CROWLEY, KENTON L.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101AFI20180109BHEP

Ipc: A61K 36/752 20060101ALI20180109BHEP

Ipc: A61K 47/44 20170101ALI20180109BHEP

Ipc: A61K 47/36 20060101ALI20180109BHEP

Ipc: A61K 47/30 20060101ALI20180109BHEP

Ipc: A61K 36/906 20060101ALI20180109BHEP

Ipc: A61K 47/42 20170101ALI20180109BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180601

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/42 20170101ALI20180525BHEP

Ipc: A61K 36/752 20060101ALI20180525BHEP

Ipc: A61K 36/906 20060101ALI20180525BHEP

Ipc: A61K 9/20 20060101AFI20180525BHEP

Ipc: A61K 47/30 20060101ALI20180525BHEP

Ipc: A61K 47/44 20170101ALI20180525BHEP

Ipc: A61K 47/36 20060101ALI20180525BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190121

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200323

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20201021

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1378751

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210415

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015067851

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602015067851

Country of ref document: DE

Owner name: FARM TO FARMA, INC., RENO, US

Free format text: FORMER OWNER: FARM TO FARMA, INC., INCLINE VILLAGE, NV, US

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: FARM TO FARMA, INC.

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1378751

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210407

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210707

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2877361

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210807

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210708

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210809

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210707

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015067851

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210630

26N No opposition filed

Effective date: 20220110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210626

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210807

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20150626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230603

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230502

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230712

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240515

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240502

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240513

Year of fee payment: 10

Ref country code: FR

Payment date: 20240509

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407